Cyclerion Therapeutics Files Definitive Proxy Statement
Ticker: CYCN · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1755237
| Field | Detail |
|---|---|
| Company | Cyclerion Therapeutics, Inc. (CYCN) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Cyclerion's proxy statement is out for the June 16th meeting - shareholders vote on directors & more.
AI Summary
Cyclerion Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 16, 2025. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting, including the election of directors and other corporate governance issues. The company is based in Cambridge, MA, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting and provides information necessary to make informed voting decisions on company leadership and governance.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that provides information to shareholders for an upcoming meeting, not indicating any immediate financial distress or significant operational changes.
Key Players & Entities
- Cyclerion Therapeutics, Inc. (company) — Registrant
- 0001140361-25-016370 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
- 20250616 (date) — Meeting Date
- 301 BINNEY STREET, CAMBRIDGE, MA 02142 (address) — Company Business Address
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon.
When is the shareholder meeting for Cyclerion Therapeutics, Inc. scheduled?
The shareholder meeting is scheduled for June 16, 2025.
What is the filing date of this proxy statement?
The definitive proxy statement was filed on April 29, 2025.
What is the primary business of Cyclerion Therapeutics, Inc. according to the filing?
Cyclerion Therapeutics, Inc. is listed under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is Cyclerion Therapeutics, Inc. headquartered?
Cyclerion Therapeutics, Inc. is headquartered at 301 Binney Street, Cambridge, MA 02142.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Cyclerion Therapeutics, Inc. (CYCN).